PE20150022A1 - Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis - Google Patents
Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosisInfo
- Publication number
- PE20150022A1 PE20150022A1 PE2014002046A PE2014002046A PE20150022A1 PE 20150022 A1 PE20150022 A1 PE 20150022A1 PE 2014002046 A PE2014002046 A PE 2014002046A PE 2014002046 A PE2014002046 A PE 2014002046A PE 20150022 A1 PE20150022 A1 PE 20150022A1
- Authority
- PE
- Peru
- Prior art keywords
- leishmaniosis
- dronedarone
- associations
- formulations
- refers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA FORMULACION QUE COMPRENDE DRONEDARONA O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES PARA ADMINISTRACION TOPICA, QUE ES UTIL PARA EL TRATAMIENTO DE LA LEISHMANIOSIS.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261650182P | 2012-05-22 | 2012-05-22 | |
EP12306362 | 2012-10-31 | ||
EP12306472 | 2012-11-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20150022A1 true PE20150022A1 (es) | 2015-02-09 |
Family
ID=49711434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2014002046A PE20150022A1 (es) | 2012-05-22 | 2013-05-22 | Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis |
Country Status (15)
Country | Link |
---|---|
US (2) | US20150150841A1 (es) |
EP (1) | EP2852385B1 (es) |
CN (1) | CN104487068B (es) |
BR (1) | BR112014028706B1 (es) |
CO (1) | CO7160058A2 (es) |
CR (1) | CR20140526A (es) |
DO (1) | DOP2014000257A (es) |
EA (1) | EA201492173A1 (es) |
IL (1) | IL235752A0 (es) |
IN (1) | IN2014KN02584A (es) |
MX (1) | MX368416B (es) |
PE (1) | PE20150022A1 (es) |
PL (1) | PL2852385T3 (es) |
TN (1) | TN2014000484A1 (es) |
WO (1) | WO2013182423A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019025606A1 (en) * | 2017-08-03 | 2019-02-07 | Bionoox Sa | COMPOSITIONS FOR USE IN THE TREATMENT OF SKIN LEHYMANIOSIS |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2665444B1 (fr) | 1990-08-06 | 1992-11-27 | Sanofi Sa | Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant. |
JP2004518664A (ja) * | 2000-12-27 | 2004-06-24 | ジェンザイム・コーポレーション | 抗不整脈剤の調節された放出 |
FR2930150B1 (fr) * | 2008-06-24 | 2011-01-14 | Sanofi Aventis | Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang |
-
2013
- 2013-05-22 WO PCT/EP2013/060513 patent/WO2013182423A1/en active Application Filing
- 2013-05-22 CN CN201380038586.4A patent/CN104487068B/zh active Active
- 2013-05-22 EA EA201492173A patent/EA201492173A1/ru unknown
- 2013-05-22 EP EP13725136.9A patent/EP2852385B1/en active Active
- 2013-05-22 PE PE2014002046A patent/PE20150022A1/es not_active Application Discontinuation
- 2013-05-22 US US14/402,587 patent/US20150150841A1/en not_active Abandoned
- 2013-05-22 PL PL13725136T patent/PL2852385T3/pl unknown
- 2013-05-22 BR BR112014028706-6A patent/BR112014028706B1/pt active IP Right Grant
- 2013-05-22 MX MX2014014258A patent/MX368416B/es active IP Right Grant
- 2013-05-22 IN IN2584KON2014 patent/IN2014KN02584A/en unknown
-
2014
- 2014-11-14 DO DO2014000257A patent/DOP2014000257A/es unknown
- 2014-11-17 CR CR20140526A patent/CR20140526A/es unknown
- 2014-11-18 IL IL235752A patent/IL235752A0/en unknown
- 2014-11-21 TN TN2014000484A patent/TN2014000484A1/fr unknown
- 2014-12-17 CO CO14276714A patent/CO7160058A2/es unknown
-
2016
- 2016-02-01 US US15/012,810 patent/US9700540B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
IN2014KN02584A (es) | 2015-05-08 |
EP2852385A1 (en) | 2015-04-01 |
DOP2014000257A (es) | 2014-12-15 |
TN2014000484A1 (en) | 2016-03-30 |
WO2013182423A1 (en) | 2013-12-12 |
CO7160058A2 (es) | 2015-01-15 |
BR112014028706A2 (pt) | 2017-06-27 |
US20160151326A1 (en) | 2016-06-02 |
US9700540B2 (en) | 2017-07-11 |
PL2852385T3 (pl) | 2020-03-31 |
EA201492173A1 (ru) | 2015-04-30 |
IL235752A0 (en) | 2015-01-29 |
MX368416B (es) | 2019-10-02 |
CR20140526A (es) | 2014-12-01 |
CN104487068A (zh) | 2015-04-01 |
CN104487068B (zh) | 2018-09-11 |
MX2014014258A (es) | 2016-04-25 |
US20150150841A1 (en) | 2015-06-04 |
BR112014028706B1 (pt) | 2023-01-10 |
EP2852385B1 (en) | 2019-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20150629A (es) | Compuestos químicos | |
CL2016000882A1 (es) | Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15). | |
CL2016001547A1 (es) | Composiciones para el cuidado oral | |
CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
GT201400196A (es) | Compuestos de heterociclilo | |
CL2015002733A1 (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
UY35040A (es) | Pirrolopirimidinilamino-benzotiazolonas sustituidas | |
MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
CL2015000345A1 (es) | Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib. | |
GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
NI201500096A (es) | Compuesto químicos | |
SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
DOP2016000007A (es) | Pirazolpiridinas sustituidas | |
UY35848A (es) | Tienopirimidinas | |
PE20142457A1 (es) | Compuestos heterociclicos y sus usos | |
CL2017000845A1 (es) | Inhibidores de gingipaina de lisina | |
CL2015001748A1 (es) | Formulaciones antiparasitarias transdermicas | |
PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
CL2012003282A1 (es) | Composicion farmaceutica topica que comprende, en base al peso total de la composicion a) 0,01 a 0,2% en peso de furoato de mometasona, b) 5 a 18% en peso de hexilenglicol, c) 20 a 40% en peso de agua y d) 25 a 70% en peso de una fase oleosa; y su uso para tratar o prevenir psoriasis, dermatitis atopica, entre otros. | |
BR112014029874A8 (pt) | composição farmacêutica do tipo emulsão óleo em água, composições e uso da composição farmacêutica | |
CL2015001502A1 (es) | Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma. | |
CL2013003588A1 (es) | Composicion farmaceutica en forma de suspension oral que comprende como principio activo una fraccion de flavonoide y como excipiente goma de xantano en la cantidad de 0,30 %p/p a 0,60 %p/p; uso para el tratamiento de la insuficiencia venosa. | |
CL2016000397A1 (es) | Tratamiento contra el cáncer | |
PE20150022A1 (es) | Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |